Andrew Benjamin Nixon, PhD

Professor in Medicine
Member of the Duke Cancer Institute
Campus mail 133 Jones, Research Drive, Durham, NC 27710
Phone (919) 613-7883
Email address anixon@duke.edu

Andrew Nixon, PhD, MBA (Associate Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Education and Training

  • Ph.D., Wake Forest University, 1997

Publications

Bergsland, Emily K., Michelle R. Mahoney, Timothy R. Asmis, Nathan Hall, Priya Kumthekar, Michael L. Maitland, Donna Niedzwiecki, et al. “Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202).” In Journal of Clinical Oncology, 37:4005–4005. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.4005.

Full Text

Hsi, Eric D., Hongli Li, Andrew B. Nixon, Heiko Schöder, Nancy L. Bartlett, Michael LeBlanc, Sonali Smith, et al. “Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.” Blood 133, no. 16 (April 18, 2019): 1762–65. https://doi.org/10.1182/blood-2018-08-870915.

PMID
30723079
Full Text

Liu, Yingmiao, Kirsten Burdett, Mark D. Starr, J Chris Brady, Ace Joseph Hatch, Anastasia Ivanova, Dominic T. Moore, et al. “Blood-based biomarkers in metastatic colorectal cancer patients treated with FOLFIRI plus regorafenib or placebo: Results from LCCC1029.” In Journal of Clinical Oncology, 37:587–587. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.4_suppl.587.

Full Text

Hatch, Ace Joseph, Fang-Shu Ou, Tyler Zemla, Mark D. Starr, John C. Brady, Yingmiao Liu, Federico Innocenti, et al. “On-treatment changes of plasma protein biomarkers in CALGB/SWOG 80405 (Alliance).” In Journal of Clinical Oncology, 37:588–588. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.4_suppl.588.

Full Text

Choueiri, Toni K., M Dror Michaelson, Edwin M. Posadas, Guru P. Sonpavde, David F. McDermott, Andrew B. Nixon, Yingmiao Liu, et al. “An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma.” Oncologist 24, no. 2 (February 2019): 202–10. https://doi.org/10.1634/theoncologist.2018-0299.

PMID
30190302
Full Text

Innocenti, Federico, Chen Jiang, Alexander B. Sibley, Amy S. Etheridge, Ace J. Hatch, Stefanie Denning, Donna Niedzwiecki, et al. “Genetic variation determines VEGF-A plasma levels in cancer patients.” Sci Rep 8, no. 1 (November 5, 2018): 16332. https://doi.org/10.1038/s41598-018-34506-4.

PMID
30397360
Full Text

Melosky, Barbara, David A. Reardon, Andrew B. Nixon, Janakiraman Subramanian, Angel H. Bair, and Ira Jacobs. “Bevacizumab biosimilars: scientific justification for extrapolation of indications.” Future Oncol 14, no. 24 (October 2018): 2507–20. https://doi.org/10.2217/fon-2018-0051.

PMID
29690784
Full Text

Liu, Yingmiao, Mark D. Starr, John C. Brady, Christel Rushing, Herbert Pang, Bonne Adams, Delia Alvarez, Charles P. Theuer, Herbert I. Hurwitz, and Andrew B. Nixon. “Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105.” Mol Cancer Ther 17, no. 10 (October 2018): 2248–56. https://doi.org/10.1158/1535-7163.MCT-17-0916.

PMID
29997150
Full Text

Vlahovic, Gordana, Kellen L. Meadows, Ace J. Hatch, Jingquan Jia, Andrew B. Nixon, Hope E. Uronis, Michael A. Morse, et al. “A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.” Oncologist 23, no. 7 (July 2018): 782–90. https://doi.org/10.1634/theoncologist.2016-0377.

PMID
29572245
Full Text

Pages